Skip to main content
SpringerLink
Log in

Nonavalent vaccine for school-based HPV vaccination programme in Singapore: benefits at high cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Phua LC, et al. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine : 18 Mar 2021. Available from: URL: http://doi.org/10.1016/j.vaccine.2021.03.040

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nonavalent vaccine for school-based HPV vaccination programme in Singapore: benefits at high cost. PharmacoEcon Outcomes News 875, 19 (2021). https://doi.org/10.1007/s40274-021-7598-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7598-y

Search

Navigation